Lauren Ezzell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lauren Ezzell has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Aaron H. Phillips
Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, Tennessee
10 shared publications - Amit Kumar
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 shared publications - Beisi Xu
Center for Applied Bioinformatics, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
10 shared publications - Burgess B. Freeman
St. Jude Children's Research Hospital
10 shared publications - Chandra Rolle
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee
10 shared publications - Clive S. D’santos
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom
10 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 7 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Eltanexor treatment in primary human cells. (A–B) Flow cytometry gating and representative plots related to Figures 5C–E. (C) CellTiter-Glo assay in CD34⁺ cells expressing UBTF-TD or UBTF-TD-NES-M. (D) HOXA/B gene expression heatmap after DMSO, dTAG-13, or eltanexor treatment. (E) UpSet plot showing UBTF-TD and XPO1 gene occupancy changes. (F–G) Design and results of colony-forming assays in UBTF-TD PDX cells treated with eltanexor.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 7 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Eltanexor treatment in primary human cells. (A–B) Flow cytometry gating and representative plots related to Figures 5C–E. (C) CellTiter-Glo assay in CD34⁺ cells expressing UBTF-TD or UBTF-TD-NES-M. (D) HOXA/B gene expression heatmap after DMSO, dTAG-13, or eltanexor treatment. (E) UpSet plot showing UBTF-TD and XPO1 gene occupancy changes. (F–G) Design and results of colony-forming assays in UBTF-TD PDX cells treated with eltanexor.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Illustrates XPO1 occupancy dynamics in cbCD34⁺ cells over time.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Illustrates XPO1 occupancy dynamics in cbCD34⁺ cells over time.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S7 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Supplemental Table 1: qPLEX RIME data. Supplemental Table 2: Identification of Nuclear Export Signals in 97 cases of UBTF-TD AML/MDS. Supplemental Table 3: Protein-coding sequences used in protein purification studies. Supplemental Table 4: NES mutation strategy in UBTF-TD constructs. Supplemental Table 5: SPR data Quantification. Supplemental Table 6: qPlEX RIME data Second Run. Supplemental Table 7: Antibodies.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S7 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Supplemental Table 1: qPLEX RIME data. Supplemental Table 2: Identification of Nuclear Export Signals in 97 cases of UBTF-TD AML/MDS. Supplemental Table 3: Protein-coding sequences used in protein purification studies. Supplemental Table 4: NES mutation strategy in UBTF-TD constructs. Supplemental Table 5: SPR data Quantification. Supplemental Table 6: qPlEX RIME data Second Run. Supplemental Table 7: Antibodies.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Displays representative sensograms illustrating the binding of XPO1/RanGTP–RanBP1 to surface-bound cargo proteins at varying concentrations.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Displays representative sensograms illustrating the binding of XPO1/RanGTP–RanBP1 to surface-bound cargo proteins at varying concentrations.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Illustrates chromatin protein interactions involving UBTF-TD54–NES-M in K562 cells using qPLEX-RIME. Panel A outlines the experimental design. Panels B and C present volcano plots comparing UBTF-TD54–NES-M to UBTF-WT and NES-M, respectively.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Illustrates chromatin protein interactions involving UBTF-TD54–NES-M in K562 cells using qPLEX-RIME. Panel A outlines the experimental design. Panels B and C present volcano plots comparing UBTF-TD54–NES-M to UBTF-WT and NES-M, respectively.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Flow cytometry analysis in UBTF-TD PDX models. (A) Gating strategy for peripheral blood and bone marrow used in Figures 6 and 7. (B–C) Representative plots and summary of peripheral blood chimerism following eltanexor treatment. (D–E) Representative flow cytometry plots from Figures 6D and 7E.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Flow cytometry analysis in UBTF-TD PDX models. (A) Gating strategy for peripheral blood and bone marrow used in Figures 6 and 7. (B–C) Representative plots and summary of peripheral blood chimerism following eltanexor treatment. (D–E) Representative flow cytometry plots from Figures 6D and 7E.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Depicts genomic occupancy of HA-tagged UBTF constructs and XPO1 at rDNA loci in cbCD34⁺ cells using CUT&RUN.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Depicts genomic occupancy of HA-tagged UBTF constructs and XPO1 at rDNA loci in cbCD34⁺ cells using CUT&RUN.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Shows String-DB analyses comparing protein enrichment in UBTF-TD versus UBTF-WT qPLEX-RIME datasets. Panel A highlights biological processes associated with commonly enriched proteins, while Panel B focuses on processes linked to proteins specifically enriched in UBTF-TD.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Shows String-DB analyses comparing protein enrichment in UBTF-TD versus UBTF-WT qPLEX-RIME datasets. Panel A highlights biological processes associated with commonly enriched proteins, while Panel B focuses on processes linked to proteins specifically enriched in UBTF-TD.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Panel A shows western blot analysis (anti-HA) of cbCD34⁺ cell lysates transduced with various HA-tagged UBTF constructs and vector control. Panel B presents RNA-seq tracks visualized in IGV, highlighting soft-clipped reads that indicate tandem duplications and the expressed cDNA sequences. Panel D-F depict gating strategies and representative flow plots
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
Panel A shows western blot analysis (anti-HA) of cbCD34⁺ cell lysates transduced with various HA-tagged UBTF constructs and vector control. Panel B presents RNA-seq tracks visualized in IGV, highlighting soft-clipped reads that indicate tandem duplications and the expressed cDNA sequences. Panel D-F depict gating strategies and representative flow plots
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (1) , 51-67
Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
UBTF tandem duplications (UBTF-TD) define a high-risk molecular subtype of acute myeloid leukemia (AML). Although menin inhibitors show therapeutic promise in UBTF-TD AMLs, acquired resistance remains a challenge. In this study, we used proteomic, epigenetic, and functional analyses to uncover mechanisms underlying UBTF-TD leukemogenesis. Biochemical studies showed that UBTF-TDs result in structural destabilization and create nuclear export signal (NES) motifs, which mediate direct interactions with exportin-1 (XPO1). In cord blood CD34+ UBTF-TD models, these interactions were shown to drive aberrant chromatin binding and transcriptional activation of genes dysregulated in UBTF-TD tumors. Through mutagenesis, we demonstrated that these NES motifs are critical for localization of UBTF-TD proteins to chromatin, transcriptional dysregulation, and cellular proliferation and differentiation. In preclinical UBTF-TD models of human leukemia, we found that XPO1 inhibition disrupts UBTF-TD chromatin localization, reduces tumor burden, and promotes differentiation. These mechanistic findings highlight XPO1 inhibition as a potential therapy for UBTF-TD AMLs. Significance: UBTF tandem duplications are a high-risk AML subtype. We identified a mechanism in which UBTF-TDs result in the generation of NES motifs, enabling aberrant interaction with XPO1. We found that XPO1 inhibitors block this interaction and impair leukemia growth, identifying a possible therapeutic strategy in UBTF-TD AML. See related commentary by Adams, p. 15
- 3 November 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (1) , 51-67
Open AccessTandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency
UBTF tandem duplications (UBTF-TD) define a high-risk molecular subtype of acute myeloid leukemia (AML). Although menin inhibitors show therapeutic promise in UBTF-TD AMLs, acquired resistance remains a challenge. In this study, we used proteomic, epigenetic, and functional analyses to uncover mechanisms underlying UBTF-TD leukemogenesis. Biochemical studies showed that UBTF-TDs result in structural destabilization and create nuclear export signal (NES) motifs, which mediate direct interactions with exportin-1 (XPO1). In cord blood CD34+ UBTF-TD models, these interactions were shown to drive aberrant chromatin binding and transcriptional activation of genes dysregulated in UBTF-TD tumors. Through mutagenesis, we demonstrated that these NES motifs are critical for localization of UBTF-TD proteins to chromatin, transcriptional dysregulation, and cellular proliferation and differentiation. In preclinical UBTF-TD models of human leukemia, we found that XPO1 inhibition disrupts UBTF-TD chromatin localization, reduces tumor burden, and promotes differentiation. These mechanistic findings highlight XPO1 inhibition as a potential therapy for UBTF-TD AMLs. Significance: UBTF tandem duplications are a high-risk AML subtype. We identified a mechanism in which UBTF-TDs result in the generation of NES motifs, enabling aberrant interaction with XPO1. We found that XPO1 inhibitors block this interaction and impair leukemia growth, identifying a possible therapeutic strategy in UBTF-TD AML. See related commentary by Adams, p. 15